🇺🇸 FDA
Patent

US 7585842

Human kunitz-type inhibitor with enhanced antifibrinolytic activity

granted A61KA61K38/00A61P

Quick answer

US patent 7585842 (Human kunitz-type inhibitor with enhanced antifibrinolytic activity) held by The Regents of the University of California expires Mon Sep 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Sep 08 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K38/00, A61P, A61P11/06, A61P29/00